CHMP adopts positive opinion for BALVERSA (erdafitinib) in unresectable/metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations July 9, 2024
FDA Granted Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic CRPC July 9, 2024
Imfinzi demonstrated statistically significant and clinically meaningful improvement in EFS and OS for MIBC in NIAGARA Ph 3 trial July 1, 2024
First-Patient-In Announced for Ph 1 Trial of IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer July 1, 2024
New Efficacy Data For RCC From KEYNOTE-B61 Added To Lenvima® (Lenvatinib) US Label Supporting Keytruda + Lenvima Indication For The 1L Treatment July 1, 2024
Unprecedented 82.3% DOR at 12 Months in the ENVISION Trial Investigating UGN-102 as a Non-Surgical Treatment for LG-IR-NMIBC announced June 18, 2024
FDA Approved Ph 2/3 Study of KPG-121 + Abiraterone combination as 1L Treatment for metastatic CRPC June 11, 2024
FAILED TRIAL: Confirmatory Ph 3 TROPiCS-04 study in locally advanced/metastatic urothelial cancer (mUC) did not meet the primary endpoint of OS in the ITT population June 4, 2024
European Commission Approves Opdivo, Cisplatin and Gemcitabine combo for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma June 4, 2024
MHRA approves expansion of ModiFY trial; Modi-1 to be assessed in RCC in combination with double CPIs May 31, 2024
5 patients deaths reported the next day after update provided on Interim TAMARACK Ph 2 Study Data May 15, 2024
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer May 15, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC May 7, 2024
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer May 7, 2024
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk NMIBC May 7, 2024
Ph 2 data for ERLEADA + ADT after radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than 2 years post-surgery May 7, 2024
Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk NMIBC Announced May 7, 2024
$15 million CIRM Grant Supports the Ongoing Ph 1 TRAVERSE Trial of ALLO-316 in Patients with Advanced or Metastatic RCC May 1, 2024
